Entries by Dana Fowlkes

May 1, 2017:

FORGE Life Science secures a second in-kind services investment from BioArdis, LLC, expanding FORGE medicinal chemistry and DMPK research resources to include BioDuro, global provider of contract research services.

February 21, 2017:

FORGE Life Science Board of Directors meeting with new external members Richard J. Whitley, Brian Pusch, Steven Holtzman joining Founders Thomas E. Shenk and Lillian W. Chiang on the Board.

JANUARY 9-11, 2017:

FORGE Life Science President & CEO, Lillian Chiang, presents at 9th Annual Biotech Showcase 2017 investor conference in San Francisco, CA.

October 27, 2016:

FORGE Life Science Board Chairman, Thomas Shenk, presents at China Renaissance’s 4th Healthcare and Life Sciences Leadership Summit in Shanghai, China.

October 20, 2016:

BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more.

October 20, 2016

BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more

September 20, 2016:

FORGE Life Science named one of 2016’s Best University Startups by the National Council of Entrepreneurial Tech Transfer (NCET2). Read more

August 5, 2016:

FORGE Life Science is awarded its fourth grant from the NIH National Institute for Allergy and Infectious Disease titled, ”Sirtuin Agonists as Pan-Influenza Antivirals” (1R44AI122488-01). Read more

June 27, 2016:

Mid Atlantic Bio Angels chooses FORGE Life Science for its first Closed-End Investing Pool investment. Read more

June 1, 2016:

FORGE Life Science secures an in-kind services investment from ShangPharma Investment Group Limited providing FORGE medicinal chemistry and DMPK contract research services from the service division of the ShangPharma group, ChemPartner, a leading contract research organization.